Global Blood Therapeutics, Inc.

NasdaqGS:GBT Voorraadrapport

Marktkapitalisatie: US$4.6b

Global Blood Therapeutics Beheer

Beheer criteriumcontroles 4/4

De CEO Global Blood Therapeutics is Ted Love, benoemd in Jun2014, heeft een ambtstermijn van 8.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.19M, bestaande uit 8.7% salaris en 91.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.37% van de aandelen van het bedrijf, ter waarde $ 63.19M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.5 jaar en 5.8 jaar.

Belangrijke informatie

Ted Love

Algemeen directeur

US$8.2m

Totale compensatie

Percentage CEO-salaris8.7%
Dienstverband CEO8.3yrs
Eigendom CEO1.4%
Management gemiddelde ambtstermijn6.5yrs
Gemiddelde ambtstermijn bestuur5.8yrs

Recente managementupdates

Recent updates

Global Blood Therapeutics expects to complete Pfizer deal in early October

Sep 30

Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals

Sep 16

Pfizer said to have had bidding war with Johnson & Johnson for Global Blood

Aug 24

What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics

Aug 08

Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil

Jul 14

GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease

Jun 29

Global Blood Therapeutics: Powerhouse Of The Future

Jun 21

Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt

Jun 07
Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt

Global Blood Therapeutics: Hitting A Growth Inflection

Apr 12

Global Blood Therapeutics: Changing My Strategy After Recent Earnings

Mar 12

Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?

Feb 24
Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?

Global Blood Therapeutics: Revisiting A Stellar Grower

Dec 25

IBI Research On Global Blood Therapeutics: Galvanized For Growth

Nov 30

Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt

Nov 03
Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt

Global Blood Therapeutics: It Might Be Time To Buy The Dip

Oct 24

Global Blood Therapeutics: Attempting To Classify The Investment

Aug 07

Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Jul 08
Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why

Jun 12
Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why

Global Blood Therapeutics announces employment inducement grants

Jun 04

Global Blood Therapeutics: Increasing Specialization In SCD

May 09

Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?

Mar 18
Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?

Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Feb 20
Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)

Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?

Jan 25
Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?

Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?

Dec 29
Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?

Analyse CEO-vergoeding

Hoe is Ted Love's beloning veranderd ten opzichte van Global Blood Therapeutics's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2022n/an/a

-US$322m

Mar 31 2022n/an/a

-US$310m

Dec 31 2021US$8mUS$716k

-US$303m

Sep 30 2021n/an/a

-US$277m

Jun 30 2021n/an/a

-US$266m

Mar 31 2021n/an/a

-US$249m

Dec 31 2020US$18mUS$661k

-US$248m

Sep 30 2020n/an/a

-US$282m

Jun 30 2020n/an/a

-US$286m

Mar 31 2020n/an/a

-US$291m

Dec 31 2019US$10mUS$597k

-US$267m

Sep 30 2019n/an/a

-US$220m

Jun 30 2019n/an/a

-US$199m

Mar 31 2019n/an/a

-US$182m

Dec 31 2018US$10mUS$569k

-US$174m

Sep 30 2018n/an/a

-US$166m

Jun 30 2018n/an/a

-US$152m

Mar 31 2018n/an/a

-US$135m

Dec 31 2017US$8mUS$520k

-US$117m

Sep 30 2017n/an/a

-US$103m

Jun 30 2017n/an/a

-US$95m

Mar 31 2017n/an/a

-US$89m

Dec 31 2016US$1mUS$479k

-US$82m

Sep 30 2016n/an/a

-US$71m

Jun 30 2016n/an/a

-US$65m

Mar 31 2016n/an/a

-US$58m

Dec 31 2015US$2mUS$438k

-US$51m

Compensatie versus markt: De totale vergoeding ($USD 8.19M ) Ted } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 6.65M ).

Compensatie versus inkomsten: De vergoeding van Ted is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ted Love (63 yo)

8.3yrs

Tenure

US$8,193,309

Compensatie

Dr. Ted W. Love, M.D., serves as Independent Director at Royalty Pharma plc since July 30, 2020. He serves as Director of Seagen Inc. (formerly known as Seattle Genetics, Inc.). since August 2020. He serve...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Ted Love
President8.3yrsUS$8.19m1.37%
$ 63.2m
Jeffrey Farrow
CFO & Principal Accounting Officer6.5yrsUS$2.76m0.040%
$ 1.8m
Jung Choi
Chief Business & Strategy Officer7.5yrsUS$2.73m0.37%
$ 17.2m
David Johnson
Chief Commercial Officer4.6yrsUS$2.75m0.084%
$ 3.9m
Kim Smith-Whitley
Executive VP and Head of Research & Development1.4yrsUS$2.98m0.0089%
$ 409.5k
David Phillips
Founder & Advisor11.8yrsgeen gegevensgeen gegevens
Matthew Jacobson
Founder & Advisor11.8yrsgeen gegevensgeen gegevens
Andrej Sali
Founder & Advisor11.8yrsgeen gegevensgeen gegevens
Nazila Habibizad
Executive Vice President of Operations2.5yrsgeen gegevens0.062%
$ 2.9m
Stephanie Yao
Senior Director of Corporate Communications & Investor Relationsno datageen gegevensgeen gegevens
Patricia Suvari
Chief Legal Officer & Secretary6yrsUS$5.93m0.064%
$ 3.0m
Steven Immergut
Senior VP & Head of Corporate Communications3.8yrsgeen gegevensgeen gegevens

6.5yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van GBT is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.5 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Ted Love
President9.1yrsUS$8.19m1.37%
$ 63.2m
Mark Perry
Lead Independent Director7.5yrsUS$348.28k0.056%
$ 2.6m
Wendy Yarno
Independent Director4.8yrsUS$320.78k0.017%
$ 783.3k
Deval Patrick
Independent Director2.4yrsUS$313.28k0.013%
$ 618.8k
Glenn Pierce
Independent Director6.7yrsUS$318.28k0.039%
$ 1.8m
Philip Pizzo
Independent Director7.1yrsUS$310.78k0.013%
$ 623.9k
Scott W. Morrison
Independent Director6.8yrsUS$333.28k0.0098%
$ 454.8k
Dawn Svoronos
Independent Director3.8yrsUS$316.36k0.0080%
$ 368.3k
Willie Brown
Advisor & Director Emeritusless than a yearUS$308.28k0.058%
$ 2.7m
Alexis Thompson
Independent Director1.6yrsUS$735.61k0.0049%
$ 226.5k

5.8yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van GBT wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.8 jaar).